MYH9 and neoplasm: Zhang et al. also demonstrated similar effects of MRPL23-AS1 overexpression on OS in in vitro and in vivo osteosarcoma models, which may be attributed to increased viability and invasiveness of cancer cells [26] Researchers have also reported that MRPL23-AS1 predominantly localizes to the cytoplasm of osteosarcoma cells, where it binds to miR-30b, leading to increased MYH9 levels and activation of the Wnt/β-catenin signaling pathway, a well-known driver of tumor progression.